РОЛЬ ПОЛИМОРФИЗМА НЕКОТОРЫХ ГЕНОВ-КАНДИДАТОВ УЧАСТВУЮЩИХ В ПАТОГЕНЕЗЕ СИНДРОМА ПОЛИКИСТОЗНЫХ ЯИЧНИКОВ
Keywords:
синдром поликистозных яичников, гиперандрогения, стероидогенез яичников, гонадотропины, гены-кандидаты, полиморфизмAbstract
В данной обзорной статье обобщено влияние полиморфизма генов, участвующих в стероидогенезе, регуляции инсулина и гонадотропинов при развитии СПКЯ. Было доказано, что не все гены влияют на стероидогенез у женщин с СПКЯ: CYP11A, CYP17, CYP19, 17-HSD, SHBG, AR, RXR, KISS1, VDR. Кроме того, было продемонстрировано, что гены LHCGR, INSR, FSHR и GnRHR влияют на активность и контроль гонадотропинов у женщин с СПКЯ. Ожирение и метаболические последствия связаны с генами FTO, VEGF, ACE и PPARG показывает, что у пациенток с СПКЯ и ожирением были более высокие уровни интерлейкина-1, PPARG, FTO и VEGF по сравнению со здоровыми женщинами. Однако исследования показали, что СПКЯ имеет генетическую основу и что ни один отдельный ген не может полностью объяснить заболевание. В результате генетические маркеры, изученные до настоящего времени, могут помочь в диагностике синдрома и его фенотипов, что позволит более раннее вовлечение в сопутствующие заболевания и более персонализированный уход.
References
Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219–31.
Kabel AM. Polycystic ovarian syndrome: insights into pathogenesis, diagnosis, prognosis, pharmacological and non-pharmacological treat- ment. Pharm Bioprocess. 2016;4(1):7–12.
Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R, et al. Criteria, prevalence, and phenotypes of polycystic ovary syn- drome. Fertil Steril. 2016;106(1):6–15
Goodarzi MO, Carmina E, Azziz R. Dhea, dheas and pcos. J Steroid Biochem Mol Biol. 2015;145:213–25.
Fenichel P, Rougier C, Hieronimus S, Chevalier N. Which origin for polycystic ovaries syndrome: Genetic, environmental or both?. Annales d’endocrinologie. 2017;78(3):176–15.
Ropelato MG, Garcia Rudaz MC, Escobar ME, Bengolea SV, Calcagno ML, Veldhuis JD, et al. Acute effects of testosterone infusion on the serum luteinizing hormone profile in eumenorrheic and polycystic ovary syndrome adolescents. J Clin Endocrinol Metab. 2009;94(9):3602–10.
Balen A H, Conway G, Homburg R, Legro R. (Eds.) Polycystic Ovary Syndrome: A Guide to Clinical Management (1st ed.). UK: CRC Press; 2006.
Dadachanji R, Shaikh N, Mukherjee S. Genetic variants associated with hyperandrogenemia in PCOS pathophysiology. Genet Res Int. 2018;2018:7624932.
Diamanti-Kandarakis E, Argyrakopoulou G, Economou F, Kandaraki E, Koutsilieris M. Defects in insulin signaling pathways in ovarian steroi- dogenesis and other tissues in polycystic ovary syndrome (PCOS). J Steroid Biochem Mol Biol. 2008;109(3–5):242–6.
Rodriguez Paris V, Bertoldo MJ. The mechanism of androgen actions in PCOS etiology. Med Sci. 2019;7(9):89.
Shi Y, Zhao H, Shi Y, Cao Y, Yang D, Li Z, et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat Genet. 2012;44(9):1020.
Goodarzi M O. Looking for polycystic ovary syndrome genes: rational and best strategy. Semin Reprod Med. 2008;26(1):5–13.
Li Y, Liu F, Luo S, Hu H, Li X-H, Li S-W. Polymorphism T C of gene CYP17 promoter and polycystic ovary syndrome risk: a meta-analysis. Gene. 2012;495(1):16–22.
Unsal T, Konac E, Yesilkaya E, Yilmaz A, Bideci A, Onen HI, et al. Genetic polymorphisms of FSHR, CYP17, CYP1A1, CAPN10, INSR, SERPINE1 genes in adolescent girls with polycystic ovary syndrome. J Assist Reprod Genet. 2009;26(4):205–16.
Sowers MR, Wilson AL, Kardia SR, Chu J, Ferrell R. Aromatase gene (CYP 19) polymorphisms and endogenous androgen concentrations in a multiracial/multiethnic, multisite study of women at midlife. Am J Med. 2006;119(9):S23–30.
Jin J-L, Sun J, Ge H-J, Cao Y-X, Wu X-K, Liang F-J, et al. Association between CYP19 gene SNP rs2414096 polymorphism and polycystic ovary syndrome in Chinese women. BMC Med Genet. 2009;10(1):139.
Mehdizadeh A, Kalantar SM, Sheikhha MH, Aali BS, Ghanei A. Association of SNP rs. 2414096 CYP19 gene with polycystic ovarian syndrome in Iranian women. Int J Reprod Biomed. 2017;15(8):491.
Ranjith R, Rani U, Nagarajeshwari C, Unnisa W, Nalini S, Jahan P. Genetics: androgen associated gene polymorphism (s) in women with polycystic ovary syndrome from South Indian population; 2011.
Al-Salihi AR, Hamdan FB, Mutib MT. Effect of CYP19 gene on polycystic ovary syndrome phenotype in Iraqi women. Iraqi J Med Sci. 2015;13(3):272–8.
Mostafa RA, Al-Sherbeeny MM, Abdelazim IA, Fahmy AA, Farghali MM, Abdel-Fatah MA, et al. Relation between aromatase gene CYP19 variation and hyperandrogenism in polycystic ovary syndrome Egyptian women. J Infertil Reprod Biol. 2016;4:1–5.
Xu P, Zhang X, Xie G, Zhang C, Shen S, Zhang X, et al. The (TTTA) n polymorphism in intron 4 of CYP19 and the polycystic ovary syndrome risk in a Chinese population. Mol Biol Rep. 2013;40(8):5041–7.
Lazaros L, Xita N, Hatzi E, Takenaka A, Kaponis A, Makrydimas G. et al. CYP19 gene variants affect the assisted reproduction outcome of women with polycystic ovary syndrome. Gynecol Endocrinol. 2013;29(5):478–82.
Hao C, Zhang N, Qu Q, Wang X, Gu HF, Chen ZJ. Evaluation of the association between the CYP19 tetranucleotide (TTTA) n polymor- phism and polycystic ovarian syndrome (PCOS) in Han Chinese women. Neuroendocrinol Lett. 2010;31(3):370–4.
Chen Z, Shi Y, Zhao Y, Li Y, Tang R, Zhao L, et al. Correlation between single nucleotide polymorphism of insulin receptor gene with polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi. 2004;39(9):582.
Lee E-J, Yoo K-J, Kim S-J, Lee S-H, Cha KY, Baek K-H, et al. Single nucleotide polymorphism in exon 17 of the insulin receptor gene is not associated with polycystic ovary syndrome in a Korean population. Fertil Steril. 2006;86(2):380–4.
Capalbo A, Sagnella F, Apa R, Fulghesu A, Lanzone A, Morciano A et al. The 312 N variant of the luteinizing hormone/choriogonadotro- pin receptor gene (LHCGR) confers up to 2 7-fold increased risk of polycystic ovary syndrome in a S ardinian population. Clin Endocrinol. 2012;77(1):113–9.
Wu X-Q, Xu S-M, Liu J-F, Bi X-Y, Wu Y-X, Liu J, et al. Association between FSHR polymorphisms and polycystic ovary syndrome among Chinese women in north China. J Assist Reprod Genet. 2014;31(3):371–7.
Kim KS, Choi SM, Shin SU, Yang HS, Yoon Y. Effects of peroxisome prolif- erator-activated receptor-γ2 Pro12Ala polymorphism on body fat distri- bution in female Korean subjects. Metabolism. 2004;53(12):1538–43.
Tönjes A, Scholz M, Loeffler M, Stumvoll M. Association of Pro12Ala polymorphism in peroxisome proliferator–activated receptor γ with pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care. 2006;29(11):2489–97.
Baldani DP, Skrgatic L, Cerne JZ, Ferk P, Simunic V, Gersak K. Association of PPARG Pro12Ala polymorphism with insulin sensitivity and body mass index in patients with polycystic ovary syndrome. Biomed Rep. 2014;2(2):199–206.
San-Millán JL, Escobar-Morreale HF. The role of genetic variation in peroxisome proliferator-activated receptors in the polycystic ovary syndrome (PCOS): an original case–control study followed by system- atic review and meta-analysis of existing evidence. Clin Endocrinol. 2010;72(3):383–92.
Dragojevič J, Ostanek B, Mencej-Bedrač S, Komadina R, Preželj J, Marc J. PPARG gene promoter polymorphism is associated with non-traumatic hip fracture risk in the elderly Slovenian population: a pilot study. Clin Biochem. 2011;44(13):1085–9.
Fan Y-S, Sasi R, Lee C, Winter J, Waterman M, Lin C. Localization of the human CYP17 gene (cytochrome P45017α) to 10q24. 3 by fluorescence in situ hybridization and simultaneous chromosome banding. Genom- ics. 1992;14(4):1110–1.
Prapas N, Karkanaki A, Prapas I, Kalogiannidis I, Katsikis I, Panidis D. Genetics of polycystic ovary syndrome. Hippokratia. 2009;13(4):216.
Wickenheisser JK, Nelson-DeGrave VL, McAllister JM. Dysregulation of cytochrome P450 17α-hydroxylase messenger ribonucleic acid stability in theca cells isolated from women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(3):1720–7.
Miyoshi Y, Iwao K, Ikeda N, Egawa C, Noguchi S. Genetic polymorphism in CYP17 and breast cancer risk in Japanese women. Eur J Cancer. 2000;36(18):2375–9.
Takayama K, Suzuki T, Bulun SE, Sasano H, Yilmaz B, Sebastian S, editors. Organization of the human aromatase p450 (CYP19) gene. In: Seminars in reproductive medicine. New York: Copyright© 2004 by Thieme Medi- cal Publishers, Inc.; 2004.
de Medeiros SF, Barbosa JS, Yamamoto MMW. Comparison of steroidogenic pathways among normoandrogenic and hyperandrogenic polycystic ovary syndrome patients and normal cycling women. J Obstet Gynaecol Res. 2015;41(2):254–63.
Chen J, Shen S, Tan Y, Xia D, Xia Y, Cao Y, et al. The correlation of aromatase activity and obesity in women with or without polycystic ovary syndrome. J Ovarian Res. 2015;8(1):11.
Yu Y-Y, Sun C-X, Liu Y-K, Li Y, Wang L, Zhang W, et al. Promoter methyla- tion of CYP19A1 gene in Chinese polycystic ovary syndrome patients. Gynecol Obstet Investig. 2013;76(4):209–13.
Yang F, Ruan Y-C, Yang Y-J, Wang K, Liang S-S, Han Y-B, et al. Follicular hyperandrogenism downregulates aromatase in luteinized granulosa cells in polycystic ovary syndrome women. Reproduction. 2015;150(4):289–96.
Morel Y, Bristow J, Gitelman SE, Miller WL. Transcript encoded on the opposite strand of the human steroid 21-hydroxylase/complement component C4 gene locus. Proc Natl Acad Sci. 1989;86(17):6582–6.
Wijesuriya SD, Zhang G, Dardis A, Miller WL. Transcriptional regulatory elements of the human gene for cytochrome P450c21 (steroid 21-hydroxylase) lie within intron 35 of the linked C4B gene. J Biol Chem. 1999;274(53):38097–106.
Witchel S, Aston C. The role of heterozygosity for CYP21 in the polycystic ovary syndrome. J Pediatr Endocrinol Metab. 2000;13:1315.
Escobar-Morreale HF, San Millán JL, Smith RR, Sancho J, Witchel SF. The presence of the 21-hydroxylase deficiency carrier status in hirsute women: phenotype-genotype correlations. Fertil Steril. 1999;72(4):629–38.
Seino S, Seino M, Bell GI. Human insulin-receptor gene. Diabetes. 1990;39(2):129–33.
Jin L, Zhu X-M, Luo Q, Qian Y, Jin F, Huang H-F. A novel SNP at exon 17 of INSR is associated with decreased insulin sensitivity in Chinese women with PCOS. Mol Hum Reprod. 2006;12(3):151–5.
Feng C, Lv P-P, Yu T-T, Jin M, Shen J-M, Wang X, et al. The association between polymorphism of INSR and polycystic ovary syndrome: a meta-analysis. Int J Mol Sci. 2015;16(2):2403–25.
Rousseau-Merck M, Atger M, Loosfelt H, Milgrom E, Berger R. The chromosomal localization of the human follicle-stimulating hormone receptor gene (FSHR) on 2p21-p16 is similar to that of the luteinizing hormone receptor gene. Genomics. 1993;15(1):222–4.
Mutharasan P, Galdones E, Peñalver Bernabé B, Garcia OA, Jafari N, Shea LD, et al. Evidence for chromosome 2p16. 3 polycystic ovary syndrome susceptibility locus in affected women of European ancestry. J Clin Endocrinol Metab. 2013;98(1):E185–E90.
Goodarzi MO, Jones MR, Li X, Chua AK, Garcia OA, Chen Y-DI, et al. Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts. J Med Genet. 2012;49(2):90–5.
Eriksen MB, Brusgaard K, Andersen M, Tan Q, Altinok ML, Gaster M, et al. Association of polycystic ovary syndrome susceptibility single nucleo- tide polymorphism rs2479106 and PCOS in Caucasian patients with PCOS or hirsutism as referral diagnosis. Eur J Obstet Gynecol Reprod Biol. 2012;163(1):39–42.
Welt CK, Styrkarsdottir U, Ehrmann DA, Thorleifsson G, Arason G, Gud- mundsson JA, et al. Variants in DENND1A are associated with polycystic ovary syndrome in women of European ancestry. J Clin Endocrinol Metab. 2012;97(7):E1342–E7.
Gromoll J, Ried T, Holtgreve-Grez H, Nieschlag E, Gudermann T. Localization of the human FSH receptor to chromosome 2 p21 using a genomic probe comprising exon 10. J Mol Endocrinol. 1994;12(3):265–71.
Gromoll J, Simoni M. Genetic complexity of FSH receptor function. Trends Endocrinol Metab. 2005;16(8):368–73.
Qiu L, Liu J, Hei Q-M. Association between two polymorphisms of folli- cle stimulating hormone receptor gene and susceptibility to polycystic ovary syndrome: a meta-analysis. Chin Med Sci J. 2015;30(1):44–50.
Louwers YV, Stolk L, Uitterlinden AG, Laven JS. Cross-ethnic meta-analysis of genetic variants for polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98(12):E2006–E12.
Beamer BA, Negri C, Yen C-J, Gavrilova O, Rumberger JM, Durcan MJ, et al. Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-gamma (hPPARγ) gene. Biochem Biophys Res Commun. 1997;233(3):756–9.
Zaki M, Hassan N, El-Bassyouni HT, Kamal S, Basha W, Azmy O, et al. Association of the Pro12Ala polymorphism with the metabolic param- eters in women with polycystic ovary syndrome. Open Access Maced J Med Sci. 2017;5(3):275.
Haap M, Machicao F, Stefan N, Thamer C, Tschritter O, Schnuck F, et al. Genetic determinants of insulin action in polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2005;113(05):275–81.
Xita N, Lazaros L, Georgiou I, Tsatsoulis A. The Pro12Ala polymorphism of the PPAR-γ gene is not associated with the polycystic ovary syn- drome. Hormones. 2009;8(4):267–72.
